Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
Chugai Pharmaceutical’s sales and profits for the fiscal year ended December 2023 contracted by two digits over the year due to a smaller supply of the COVID-19 treatment Ronapreve (casirivimab/imdevimab) to the government as well as to generic penetrations. Its…
To read the full story
Related Article
- Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition
April 25, 2024
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
BUSINESS
- AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…